ClinicalTrials.gg
CompletedNCT04092452Updated Jun 15, 2023Results posted

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

A Phase 2 interventional study of PF-06650833 and PF-06700841 in Acne Inversa, sponsored by Pfizer. Completed at 77 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
41st of 139
194 · median 45
Started
2019
with 11 others
Phase 2
61 of 161
11 open now
Registered
49th of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 41st largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2019, is one of 61 in phase 2, and was the 49th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

03

Conditions studied

  • Acne Inversa
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female participants, between 18-75, with a diagnosis of moderate to severe Hidradenitis Suppurativa

Exclusion criteria

Exclusion Criteria:

  • History of (HIV) or positive HIV serology at screening,
  • Infected with or viruses.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Cohort 1

    PF-06650833

    Drug: PF-06650833

  • Experimental
    Cohort 2

    PF-6700841

    Drug: PF-06700841

  • Experimental
    Cohort 3

    PF-06826647

    Drug: PF-06826647

  • Placebo comparator
    Cohort placebo

    placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)].

    HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At week 16

Secondary outcomes

  1. Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI).

    HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At weeks 1, 2, 4, 6, 8, and 12

  2. Percentage of Participants Achieving a Total Abscess and Inflammatory Nodule (AN) Count of 0 or 1; 0, 1 or 2 at Week 16 - MR (FAS, NRI).

    This estimand was intended to provide difference between treated and placebo in percentage of participants with a total AN count of 0 or 1, or 0, 1 or 2, respectively at week 16. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At week 16

  3. Least Squares (LS) Mean of Percent Change From Baseline in AN Count at Weeks 1, 2, 4, 6, 8, 12 and 16 - Analysis of Covariance (ANCOVA) [FAS, Multiply Imputed (MI)].

    The analysis of covariance (ANCOVA) model was implemented for statistical testing, which included terms of treatment group, the stratification factors, and the baseline value as the independent variable.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  4. Least Squares Mean of Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).

    The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  5. Least Squares Mean of Percent Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).

    The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  6. Percentage of Participants Who Experienced a Hidradenitis Suppurativa (HS) Flare at Weeks 4, 8, 12 and 16 - MR [FAS, Only Observed Data (OBS)].

    HS flare was defined as at least a 25% increase in AN count with a minimum increase of 2 relative to Baseline. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At weeks 4, 8, 12 and 16

  7. Percentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)

    The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  8. Percentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)

    The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  9. Least Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)

    Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  10. Least Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)

    Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  11. Least Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)

    Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  12. Least Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)

    Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  13. Percentage of Participants Achieving Erythema Response Among Participants With Baseline Erythema Score ≥2 in at Least 1 Region at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS, NRI)

    Erythema response was defined as achieving erythema score of 1 or 0 in all affected anatomic regions among participants who had an erythema score of 2 or more in at least 1 anatomic region at baseline. NRI for missing values which were related to withdrawal and all other events except for COVID-19. A four-point ordinal scale ranging was used: 0 (no redness), 1 (faint but discernible pink coloration), 2 (moderate red coloration), and 3 (very red or bright red coloration).

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  14. Number of Participants With Treatment-Emergent Adverse Events (All Causalities)

    The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.

    Time frame: Up to 20 weeks

  15. Number of Participants With Treatment-Emergent Adverse Events (Treatment Related)

    The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.

    Time frame: Up to 20 weeks

  16. Number of Participants With Incidence of Post-baseline Vital Signs of Clinical Concern - Increase From Baseline (Safety Analysis Set)

    The vital signs were measured included temperature (Oral, Tympanic, Axillary or Temporal), pulse rate (beats/min) and blood pressure (mmHg).

    Time frame: Up to 20 weeks

  17. Number of Participants With Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) (Safety Analysis Set)

    Laboratory test abnormalities included hematology, chemistry, urinalysis and biomarker.

    Time frame: Up to 20 weeks

  18. Number of Participants With Incidence of Post-baseline Electrocardiogram (ECG) Values of Clinical Concern (Safety Analysis Set)

    ECG parameters included QT interval, QTc interval, PR interval, and QRS complex.

    Time frame: Up to 20 weeks

  19. Least Squares Mean of Absolute Score in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - Mixed Effect Model Repeated Measurement (MMRM) (FAS, OBS)

    The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  20. Least Squares Mean of Change From Baseline in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - MMRM (FAS, OBS)

    The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

  21. Least Squares Mean of Absolute Score in Dermatology Life Quality Index (DLQI) Total Score up to Week 16 - MMRM (FAS, OBS)

    The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes.

    Time frame: At weeks 4, 8, 12 and 16

  22. Least Squares Mean of Change From Baseline in DLQI Total Score up to Week 16 - MMRM (FAS, OBS)

    The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined a change from baseline in total score, where negative value means improvement in DLQI.

    Time frame: At weeks 4, 8, 12 and 16

  23. Percentage of Participants Achieving DLQI Total Score of 0 or 1 up to Week 16 - MR (FAS With Baseline >1, NRI)

    The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined the percentage of patients with complete resolution of dermatology specific quality of life impact, as assessed by a total score of ≤ 1 (range: 0 - 30), where higher percentage indicates better improvement in DLQI.

    Time frame: At weeks 4, 8, 12 and 16

  24. Plasma Concentration Versus Time Summary (Pharmacokinetic Concentration Set)

    In summary statistics for pharmacokinetic, concentration values below the lower limit of quantification (LLOQ) was set to zero.

    Time frame: At weeks 1, 2, 4, 6, 8, 12 and 16

07

Results

Posted Jun 15, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Started48475247
Completed35303731
Not completed13171516
Withdrew: Adverse event1337
Withdrew: Lack of efficacy1110
Withdrew: Lost to follow-up4351
Withdrew: Non-compliance with study drug0011
Withdrew: Physician decision1010
Withdrew: Pregnancy2000
Withdrew: Protocol deviation1000
Withdrew: Withdrawal by subject31035
Withdrew: Other0012

Outcome measures

PrimaryPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)].

HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)].
Percentage of participantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)].33.3 (22.2 to 45.5)34.0 (22.7 to 46.5)51.9 (39.7 to 64.0)37.0 (25.5 to 50.0)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.4696 (One-sided p-value) · Risk difference (rd): 0.7 · 90% CI -15.2 to 16.7P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0298 (One-sided p-value) · Risk difference (rd): 18.7 · 90% CI 2.7 to 34.6P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.3606 (One-sided p-value) · Risk difference (rd): 3.5 · 90% CI -12.6 to 19.6P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
SecondaryPercentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI).

HiSCR response was defined as at least a 50% reduction in total abscess and inflammatory nodule (AN) count relative to baseline, and no increase in abscess count, and no increase in draining fistula count. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At weeks 1, 2, 4, 6, 8, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI).
Percentage of participantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 116.7 (8.6 to 27.7)12.8 (5.7 to 22.7)15.4 (7.9 to 25.4)21.3 (12.0 to 32.2)
Week 225.0 (15.1 to 36.9)31.9 (20.8 to 44.4)32.0 (21.2 to 43.4)28.3 (17.6 to 40.4)
Week 431.9 (20.8 to 44.4)40.4 (28.3 to 53.5)39.2 (27.7 to 51.6)27.7 (17.2 to 40.3)
Week 637.5 (26.4 to 50.0)38.3 (27.1 to 51.3)44.2 (32.4 to 56.3)41.3 (29.0 to 54.5)
Week 843.8 (31.5 to 56.6)36.2 (25.1 to 48.7)44.2 (32.4 to 56.3)41.3 (29.0 to 54.5)
Week 1241.7 (29.6 to 54.5)31.9 (20.8 to 44.4)50.0 (37.9 to 62.1)41.3 (29.0 to 54.5)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -3.8 · 90% CI -15.6 to 8.0
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.9 · 90% CI -12.9 to 11.1
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 4.6 · 90% CI -8.5 to 17.8
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 7.9 · 90% CI -6.9 to 22.8
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 7.5 · 90% CI -7.1 to 22.2
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 3.5 · 90% CI -11.3 to 18.3
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 9.0 · 90% CI -7.1 to 25.1
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 7.7 · 90% CI -8.0 to 23.5
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -4.0 · 90% CI -19.4 to 11.4
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.8 · 90% CI -15.6 to 17.2
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 6.7 · 90% CI -9.4 to 22.9
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 3.7 · 90% CI -12.8 to 20.2
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.7798 (One-sided p-value) · Risk difference (rd): -7.8 · 90% CI -24.2 to 8.7P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.4819 (One-sided p-value) · Risk difference (rd): 0.5 · 90% CI -15.9 to 16.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.5933 (One-sided p-value) · Risk difference (rd): -2.4 · 90% CI -19.2 to 14.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.8421 (One-sided p-value) · Risk difference (rd): -9.9 · 90% CI -26.1 to 6.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.2090 (One-sided p-value) · Risk difference (rd): 8.0 · 90% CI -8.2 to 24.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.5183 (One-sided p-value) · Risk difference (rd): -0.5 · 90% CI -17.1 to 16.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
SecondaryPercentage of Participants Achieving a Total Abscess and Inflammatory Nodule (AN) Count of 0 or 1; 0, 1 or 2 at Week 16 - MR (FAS, NRI).

This estimand was intended to provide difference between treated and placebo in percentage of participants with a total AN count of 0 or 1, or 0, 1 or 2, respectively at week 16. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Total Abscess and Inflammatory Nodule (AN) Count of 0 or 1; 0, 1 or 2 at Week 16 - MR (FAS, NRI).
Percentage of participantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Total AN Count of 0 or 116.7 (8.6 to 27.7)17.0 (8.8 to 28.3)28.8 (18.7 to 39.7)23.9 (15.1 to 35.0)
Total AN Count of 0, 1 or 222.9 (14.4 to 34.0)27.7 (17.2 to 40.3)38.5 (27.1 to 50.0)32.6 (21.3 to 45.5)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.5150 (One-sided p-value) · Risk difference (rd): -0.3 · 90% CI -12.7 to 12.1P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0737 (One-sided p-value) · Risk difference (rd): 12.2 · 90% CI -1.4 to 25.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.2081 (One-sided p-value) · Risk difference (rd): 6.6 · 90% CI -6.7 to 20.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.2957 (One-sided p-value) · Risk difference (rd): 4.8 · 90% CI -9.9 to 19.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0456 (One-sided p-value) · Risk difference (rd): 15.6 · 90% CI 0.7 to 30.5P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.1558 (One-sided p-value) · Risk difference (rd): 9.2 · 90% CI -5.7 to 24.1P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
SecondaryLeast Squares (LS) Mean of Percent Change From Baseline in AN Count at Weeks 1, 2, 4, 6, 8, 12 and 16 - Analysis of Covariance (ANCOVA) [FAS, Multiply Imputed (MI)].

The analysis of covariance (ANCOVA) model was implemented for statistical testing, which included terms of treatment group, the stratification factors, and the baseline value as the independent variable.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Percent change
Least Squares (LS) Mean of Percent Change From Baseline in AN Count at Weeks 1, 2, 4, 6, 8, 12 and 16 - Analysis of Covariance (ANCOVA) [FAS, Multiply Imputed (MI)].
Percent changePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1-1.94 (-12.37 to 8.50)-13.92 (-24.50 to -3.35)-17.00 (-27.35 to -6.66)-19.39 (-30.40 to -8.38)
Week 2-22.29 (-33.70 to -10.88)-34.81 (-46.81 to -22.82)-25.15 (-36.73 to -13.57)-27.79 (-39.61 to -15.96)
Week 4-26.46 (-40.31 to -12.61)-30.98 (-44.77 to -17.18)-44.00 (-57.40 to -30.59)-30.38 (-45.18 to -15.58)
Week 6-33.05 (-49.47 to -16.64)-25.96 (-42.45 to -9.47)-47.62 (-64.49 to -30.75)-42.00 (-59.13 to -24.87)
Week 8-36.26 (-52.53 to -19.98)-24.76 (-40.74 to -8.77)-52.41 (-68.05 to -36.76)-51.33 (-68.17 to -34.48)
Week 12-32.52 (-50.98 to -14.06)-39.06 (-58.63 to -19.48)-49.70 (-65.92 to -33.47)-52.51 (-70.36 to -34.66)
Week 16-34.96 (-59.85 to -10.07)-24.11 (-49.42 to 1.20)-52.58 (-76.77 to -28.39)-44.37 (-69.80 to -18.94)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -11.98 · 90% CI -26.16 to 2.20
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -15.07 · 90% CI -29.09 to -1.04
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -17.45 · 90% CI -31.86 to -3.05
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -12.52 · 90% CI -28.09 to 3.05
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -2.86 · 90% CI -18.22 to 12.50
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -5.50 · 90% CI -21.02 to 10.03
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -4.52 · 90% CI -22.96 to 13.93
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -17.54 · 90% CI -35.84 to 0.77
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -3.92 · 90% CI -22.85 to 15.00
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 7.09 · 90% CI -15.04 to 29.22
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -14.57 · 90% CI -37.08 to 7.95
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -8.95 · 90% CI -31.66 to 13.76
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.8108 (One-sided p-value) · Risk difference (rd): 11.50 · 90% CI -9.98 to 32.98
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1043 (One-sided p-value) · Risk difference (rd): -16.15 · 90% CI -37.28 to 4.98
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1296 (One-sided p-value) · Risk difference (rd): -15.07 · 90% CI -37.04 to 6.90
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.3450 (One-sided p-value) · Risk difference (rd): -6.54 · 90% CI -33.49 to 20.42
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1119 (One-sided p-value) · Risk difference (rd): -17.18 · 90% CI -40.40 to 6.04
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.0885 (One-sided p-value) · Risk difference (rd): -19.99 · 90% CI -44.34 to 4.37
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.7050 (One-sided p-value) · Risk difference (rd): 10.85 · 90% CI -22.28 to 43.98
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1833 (One-sided p-value) · Risk difference (rd): -17.62 · 90% CI -49.73 to 14.48
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.3213 (One-sided p-value) · Risk difference (rd): -9.41 · 90% CI -42.76 to 23.94
SecondaryLeast Squares Mean of Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).

The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Units on a scale
Least Squares Mean of Absolute Score in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).
Units on a scalePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1 - Statistical Analysis (MI) - Absolute Score22.9 (19.6 to 26.1)21.4 (18.1 to 24.6)20.8 (17.7 to 24.0)21.4 (18.1 to 24.7)
Week 2 - Statistical Analysis (MI) - Absolute Score18.9 (15.8 to 22.1)18.0 (14.8 to 21.2)18.8 (15.7 to 21.9)19.0 (15.7 to 22.2)
Week 4 - Statistical Analysis (MI) - Absolute Score17.9 (14.8 to 20.9)17.5 (14.4 to 20.6)16.5 (13.6 to 19.5)13.3 (10.0 to 16.7)
Week 6 - Statistical Analysis (MI) - Absolute Score19.7 (16.0 to 23.3)18.1 (14.4 to 21.7)14.9 (11.4 to 18.5)14.2 (10.3 to 18.1)
Week 8 - Statistical Analysis (MI) - Absolute Score14.9 (11.5 to 18.3)15.9 (12.5 to 19.4)15.0 (11.7 to 18.4)11.1 (7.5 to 14.7)
Week 12 - Statistical Analysis (MI) - Absolute Score15.8 (12.6 to 18.9)14.5 (11.2 to 17.8)13.0 (10.0 to 16.0)12.9 (9.5 to 16.3)
Week 16 - Statistical Analysis (MI) - Absolute Score16.0 (12.4 to 19.6)13.4 (9.5 to 17.3)12.0 (8.8 to 15.3)13.4 (9.8 to 17.0)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -1.5 · 90% CI -5.9 to 2.9
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -2.0 · 90% CI -6.3 to 2.2
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -1.5 · 90% CI -5.9 to 2.9
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.9 · 90% CI -5.2 to 3.3
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.1 · 90% CI -4.3 to 4.1
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.0 · 90% CI -4.3 to 4.3
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.3 · 90% CI -4.5 to 3.8
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.3 · 90% CI -5.4 to 2.8
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -4.5 · 90% CI -8.8 to -0.3
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -1.6 · 90% CI -6.5 to 3.3
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -4.7 · 90% CI -9.5 to 0.1
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -5.4 · 90% CI -10.5 to -0.4
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6393 (One-sided p-value) · Risk difference (rd): 1.0 · 90% CI -3.6 to 5.6
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.5178 (One-sided p-value) · Risk difference (rd): 0.1 · 90% CI -4.4 to 4.6
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.0864 (One-sided p-value) · Risk difference (rd): -3.8 · 90% CI -8.5 to 0.8
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.3172 (One-sided p-value) · Risk difference (rd): -1.2 · 90% CI -5.5 to 3.1
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1384 (One-sided p-value) · Risk difference (rd): -2.7 · 90% CI -6.8 to 1.4
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1427 (One-sided p-value) · Risk difference (rd): -2.8 · 90% CI -7.2 to 1.5
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.1975 (One-sided p-value) · Risk difference (rd): -2.5 · 90% CI -7.5 to 2.4
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0755 (One-sided p-value) · Risk difference (rd): -4.0 · 90% CI -8.5 to 0.6
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1869 (One-sided p-value) · Risk difference (rd): -2.6 · 90% CI -7.3 to 2.2
SecondaryLeast Squares Mean of Percent Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).

The IHS4 score was calculated by the number of nodules, the number of abscesses, and the number of draining tunnels. IHS4 score = (number of nodules × 1) + (number of abscesses × 2) + {number of draining tunnels (fistulae/sinuses) × 4}. Confidence interval (CI) was calculated using Blyth-Still-Casella method. Lower IHS4 absolute scores mean a better outcome.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Percent change
Least Squares Mean of Percent Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI).
Percent changePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1 - Statistical Analysis (MI) - Percent Change from Baseline-7.26 (-17.77 to 3.26)-10.91 (-21.57 to -0.25)-21.02 (-31.75 to -10.30)-24.77 (-35.94 to -13.59)
Week 2 - Statistical Analysis (MI) - Percent Change from Baseline-26.58 (-38.80 to -14.37)-30.87 (-43.51 to -18.23)-28.63 (-40.68 to -16.59)-26.41 (-38.99 to -13.84)
Week 4 - Statistical Analysis (MI) - Percent Change from Baseline-32.64 (-45.55 to -19.72)-33.10 (-45.56 to -20.65)-40.71 (-52.76 to -28.66)-38.70 (-52.26 to -25.14)
Week 6 - Statistical Analysis (MI) - Percent Change from Baseline-30.57 (-45.47 to -15.67)-34.10 (-49.16 to -19.05)-46.83 (-62.62 to -31.03)-43.09 (-59.05 to -27.13)
Week 8 - Statistical Analysis (MI) - Percent Change from Baseline-41.30 (-54.94 to -27.67)-35.51 (-49.04 to -21.98)-47.12 (-60.38 to -33.85)-52.64 (-67.14 to -38.14)
Week 12 - Statistical Analysis (MI) - Percent Change from Baseline-36.46 (-50.16 to -22.76)-43.24 (-56.66 to -29.82)-53.03 (-65.59 to -40.47)-50.11 (-65.53 to -34.70)
Week 16 - Statistical Analysis (MI) - Percent Change from Baseline-37.84 (-54.85 to -20.82)-43.47 (-60.47 to -26.47)-52.64 (-70.79 to -34.49)-46.16 (-64.20 to -28.11)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -3.65 · 90% CI -17.90 to 10.59
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -13.77 · 90% CI -28.16 to 0.62
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -17.51 · 90% CI -31.91 to -3.12
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -4.29 · 90% CI -20.91 to 12.33
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -2.05 · 90% CI -18.34 to 14.24
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.17 · 90% CI -16.34 to 16.68
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.46 · 90% CI -17.29 to 16.36
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -8.07 · 90% CI -24.77 to 8.63
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -6.06 · 90% CI -23.35 to 11.22
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -3.54 · 90% CI -23.71 to 16.63
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -16.26 · 90% CI -36.84 to 4.32
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -12.52 · 90% CI -33.27 to 8.22
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.7000 (One-sided p-value) · Risk difference (rd): 5.79 · 90% CI -12.38 to 23.96
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.2965 (One-sided p-value) · Risk difference (rd): -5.81 · 90% CI -23.70 to 12.08
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1568 (One-sided p-value) · Risk difference (rd): -11.33 · 90% CI -29.83 to 7.17
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.2672 (One-sided p-value) · Risk difference (rd): -6.78 · 90% CI -24.73 to 11.17
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0576 (One-sided p-value) · Risk difference (rd): -16.57 · 90% CI -33.87 to 0.73
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1197 (One-sided p-value) · Risk difference (rd): -13.65 · 90% CI -32.74 to 5.44
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.3388 (One-sided p-value) · Risk difference (rd): -5.63 · 90% CI -27.91 to 16.65
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1376 (One-sided p-value) · Risk difference (rd): -14.80 · 90% CI -37.12 to 7.51
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.2741 (One-sided p-value) · Risk difference (rd): -8.32 · 90% CI -31.12 to 14.48
SecondaryPercentage of Participants Who Experienced a Hidradenitis Suppurativa (HS) Flare at Weeks 4, 8, 12 and 16 - MR [FAS, Only Observed Data (OBS)].

HS flare was defined as at least a 25% increase in AN count with a minimum increase of 2 relative to Baseline. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At weeks 4, 8, 12 and 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced a Hidradenitis Suppurativa (HS) Flare at Weeks 4, 8, 12 and 16 - MR [FAS, Only Observed Data (OBS)].
Percentage of participantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 413.3 (6.0 to 23.7)11.9 (5.9 to 22.7)4.8 (1.3 to 13.5)14.3 (7.1 to 26.0)
Week 89.3 (4.1 to 18.9)15.4 (6.9 to 27.7)2.3 (0.2 to 9.4)0 (0.0 to 7.3)
Week 1217.5 (9.5 to 29.2)5.9 (1.6 to 16.9)2.4 (0.3 to 10.1)0 (0.0 to 8.2)
Week 1617.1 (7.7 to 30.2)6.9 (1.8 to 20.0)0 (0.0 to 7.3)3.3 (0.4 to 14.0)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -1.3 · 90% CI -13.0 to 10.3
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -8.5 · 90% CI -18.7 to 1.8
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 1.7 · 90% CI -10.7 to 14.1
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.8372 (One-sided p-value) · Risk difference (rd): 6.6 · 90% CI -4.6 to 17.7P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0819 (One-sided p-value) · Risk difference (rd): -6.4 · 90% CI -14.1 to 1.3P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.0242 (One-sided p-value) · Risk difference (rd): -8.0 · 90% CI -15.2 to -0.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.0264 (One-sided p-value) · Risk difference (rd): -12.7 · 90% CI -23.1 to -2.3P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0127 (One-sided p-value) · Risk difference (rd): -14.5 · 90% CI -25.1 to -3.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.0059 (One-sided p-value) · Risk difference (rd): -16.6 · 90% CI -27.0 to -6.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.1185 (One-sided p-value) · Risk difference (rd): -9.6 · 90% CI -22.7 to 3.5P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0040 (One-sided p-value) · Risk difference (rd): -16.1 · 90% CI -26.6 to -5.6P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.0418 (One-sided p-value) · Risk difference (rd): -12.8 · 90% CI -24.5 to -1.1P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
SecondaryPercentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)

The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)
Percentage of participantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1 (Pain at its Worst)7.3 (2.7 to 17.3)18.9 (10.4 to 31.8)16.7 (9.1 to 27.7)19.5 (10.1 to 31.2)
Week 2 (Pain at its Worst)17.1 (9.3 to 28.4)21.6 (11.2 to 34.3)28.6 (17.4 to 41.0)24.4 (13.9 to 37.4)
Week 4 (Pain at its Worst)34.1 (23.0 to 46.9)16.2 (7.3 to 29.3)40.5 (27.7 to 54.3)31.7 (19.9 to 44.5)
Week 6 (Pain at its Worst)41.5 (28.4 to 55.5)21.6 (11.2 to 34.3)38.1 (25.6 to 52.0)29.3 (17.8 to 42.1)
Week 8 (Pain at its Worst)34.1 (23.0 to 46.9)29.7 (18.5 to 43.3)50.0 (36.5 to 63.5)27.5 (17.5 to 40.9)
Week 12 (Pain at its Worst)43.9 (31.2 to 57.9)29.7 (18.5 to 43.3)40.5 (27.7 to 54.3)35.0 (23.4 to 48.3)
Week 16 (Pain at its Worst)29.3 (17.8 to 42.1)21.6 (11.2 to 34.3)35.7 (23.7 to 48.0)35.0 (23.4 to 48.3)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.0559 (One-sided p-value) · Risk difference (rd): 12.1 · 90% CI -0.7 to 24.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0758 (One-sided p-value) · Risk difference (rd): 9.8 · 90% CI -1.9 to 21.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.0637 (One-sided p-value) · Risk difference (rd): 11.3 · 90% CI -0.6 to 23.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.3179 (One-sided p-value) · Risk difference (rd): 4.2 · 90% CI -10.3 to 18.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.1078 (One-sided p-value) · Risk difference (rd): 11.0 · 90% CI -3.5 to 25.5P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.1976 (One-sided p-value) · Risk difference (rd): 7.6 · 90% CI -7.0 to 22.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.9738 (One-sided p-value) · Risk difference (rd): -18.9 · 90% CI -34.3 to -3.6P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.2925 (One-sided p-value) · Risk difference (rd): 5.8 · 90% CI -11.3 to 22.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.6178 (One-sided p-value) · Risk difference (rd): -3.1 · 90% CI -19.8 to 13.7P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.9769 (One-sided p-value) · Risk difference (rd): -20.9 · 90% CI -37.4 to -4.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.6529 (One-sided p-value) · Risk difference (rd): -4.2 · 90% CI -21.6 to 13.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.8878 (One-sided p-value) · Risk difference (rd): -12.8 · 90% CI -29.8 to 4.3P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.7259 (One-sided p-value) · Risk difference (rd): -6.2 · 90% CI -22.9 to 10.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0826 (One-sided p-value) · Risk difference (rd): 14.8 · 90% CI -2.1 to 31.6P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.7884 (One-sided p-value) · Risk difference (rd): -8.0 · 90% CI -24.1 to 8.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.9326 (One-sided p-value) · Risk difference (rd): -16.1 · 90% CI -33.2 to 1.1P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.6810 (One-sided p-value) · Risk difference (rd): -4.9 · 90% CI -22.1 to 12.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.8308 (One-sided p-value) · Risk difference (rd): -10.3 · 90% CI -27.6 to 7.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.8063 (One-sided p-value) · Risk difference (rd): -8.5 · 90% CI -24.5 to 7.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.2649 (One-sided p-value) · Risk difference (rd): 6.5 · 90% CI -10.4 to 23.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.3029 (One-sided p-value) · Risk difference (rd): 5.3 · 90% CI -11.7 to 22.4P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
SecondaryPercentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)

The rate comparing treatment and placebo groups at each visit was analyzed using CMH test with MR weighting strategy between each of active treatment group and placebo. Confidence interval (CI) was calculated using Blyth-Still-Casella method. NRS30 was defined as ≥30% reduction and ≥1 unit reduction from baseline in Patient's Global Assessment (PGA) Skin Pain NRS. The range of skin pain was from 0 to 10. Lower IHS4 absolute scores mean a better outcome. Baseline was defined as the average of all values recorded between Day -6 and Day 1. Weekly data were average values of daily observations over 7 days. NRI (non-responder imputation) for missing values which were related to withdrawal and all other events except for COVID-19.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Skin Pain Numeric Rating Scale (NRS30), on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS With Baseline ≥3, NRI)
Percentage of participantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1 (Average Pain)10.3 (4.5 to 21.0)17.6 (8.0 to 30.7)24.4 (13.9 to 37.4)8.6 (3.2 to 19.3)
Week 2 (Average Pain)17.9 (9.8 to 30.0)20.6 (11.3 to 34.9)36.6 (24.6 to 50.0)22.9 (11.9 to 36.5)
Week 4 (Average Pain)33.3 (21.0 to 47.1)20.6 (11.3 to 34.9)46.3 (33.9 to 60.2)34.3 (22.0 to 47.8)
Week 6 (Average Pain)48.7 (35.6 to 61.9)32.4 (19.7 to 46.2)48.8 (35.1 to 62.6)34.3 (22.0 to 47.8)
Week 8 (Average Pain)35.9 (23.9 to 50.0)26.5 (15.9 to 40.5)56.1 (42.1 to 68.8)29.4 (16.9 to 43.3)
Week 12 (Average Pain)41.0 (27.7 to 55.4)26.5 (15.9 to 40.5)41.5 (28.4 to 55.5)32.4 (19.7 to 46.2)
Week 16 (Average Pain)28.2 (17.8 to 42.1)20.6 (11.3 to 34.9)39.0 (26.2 to 53.1)32.4 (19.7 to 46.2)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.1687 (One-sided p-value) · Risk difference (rd): 7.7 · 90% CI -5.7 to 21.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0376 (One-sided p-value) · Risk difference (rd): 13.8 · 90% CI 0.6 to 27.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.5883 (One-sided p-value) · Risk difference (rd): -1.5 · 90% CI -12.9 to 9.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.3829 (One-sided p-value) · Risk difference (rd): 2.7 · 90% CI -12.2 to 17.6P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0316 (One-sided p-value) · Risk difference (rd): 18.2 · 90% CI 2.5 to 33.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.3072 (One-sided p-value) · Risk difference (rd): 4.6 · 90% CI -10.5 to 19.7P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.8952 (One-sided p-value) · Risk difference (rd): -13.1 · 90% CI -29.8 to 3.7P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.1157 (One-sided p-value) · Risk difference (rd): 13.1 · 90% CI -4.6 to 30.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.4672 (One-sided p-value) · Risk difference (rd): 0.9 · 90% CI -17.1 to 18.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.9287 (One-sided p-value) · Risk difference (rd): -16.9 · 90% CI -35.5 to 1.6P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.4984 (One-sided p-value) · Risk difference (rd): 0.0 · 90% CI -17.8 to 17.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.9001 (One-sided p-value) · Risk difference (rd): -14.7 · 90% CI -33.2 to 3.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.8319 (One-sided p-value) · Risk difference (rd): -10.3 · 90% CI -27.6 to 7.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0340 (One-sided p-value) · Risk difference (rd): 19.7 · 90% CI 2.3 to 37.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.7359 (One-sided p-value) · Risk difference (rd): -6.8 · 90% CI -24.4 to 10.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.9291 (One-sided p-value) · Risk difference (rd): -16.0 · 90% CI -33.3 to 1.3P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.5087 (One-sided p-value) · Risk difference (rd): -0.2 · 90% CI -17.4 to 16.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.8098 (One-sided p-value) · Risk difference (rd): -9.5 · 90% CI -27.2 to 8.1P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.8114 (One-sided p-value) · Risk difference (rd): -8.8 · 90% CI -24.8 to 7.2P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.1531 (One-sided p-value) · Risk difference (rd): 10.8 · 90% CI -6.4 to 28.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.3784 (One-sided p-value) · Risk difference (rd): 3.3 · 90% CI -14.1 to 20.7P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
SecondaryLeast Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)

Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Percent change
Least Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)
Percent changePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1-Pain at its Worst-1.45 (-9.33 to 6.42)-8.89 (-17.18 to -0.61)-11.97 (-19.58 to -4.37)-15.58 (-23.50 to -7.66)
Week 2-Pain at its Worst-7.49 (-17.39 to 2.42)-13.15 (-23.61 to -2.69)-19.40 (-29.09 to -9.72)-19.19 (-29.20 to -9.19)
Week 4-Pain at its Worst-18.81 (-29.31 to -8.31)-15.56 (-26.68 to -4.45)-26.63 (-36.88 to -16.37)-19.98 (-30.63 to -9.33)
Week 6-Pain at its Worst-21.80 (-33.14 to -10.47)-13.86 (-25.74 to -1.98)-32.89 (-43.90 to -21.88)-21.76 (-33.08 to -10.43)
Week 8-Pain at its Worst-23.53 (-34.49 to -12.57)-20.70 (-32.22 to -9.18)-34.83 (-45.55 to -24.11)-23.37 (-34.40 to -12.35)
Week 12-Pain at its Worst-26.04 (-37.10 to -14.98)-25.38 (-36.95 to -13.81)-41.35 (-52.12 to -30.58)-32.43 (-43.66 to -21.20)
Week 16-Pain at its Worst-22.34 (-33.82 to -10.86)-19.77 (-31.60 to -7.93)-43.88 (-55.06 to -32.70)-34.87 (-46.36 to -23.38)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.1321 (One-sided p-value) · Risk difference (rd): -7.44 · 90% CI -18.39 to 3.52
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0477 (One-sided p-value) · Risk difference (rd): -10.52 · 90% CI -20.90 to -0.14
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.0134 (One-sided p-value) · Risk difference (rd): -14.13 · 90% CI -24.62 to -3.63
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.2496 (One-sided p-value) · Risk difference (rd): -5.66 · 90% CI -19.45 to 8.12
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0675 (One-sided p-value) · Risk difference (rd): -11.92 · 90% CI -25.03 to 1.20
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.0730 (One-sided p-value) · Risk difference (rd): -11.71 · 90% CI -24.96 to 1.54
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6426 (One-sided p-value) · Risk difference (rd): 3.25 · 90% CI -11.38 to 17.88
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1776 (One-sided p-value) · Risk difference (rd): -7.82 · 90% CI -21.73 to 6.09
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.4458 (One-sided p-value) · Risk difference (rd): -1.17 · 90% CI -15.28 to 12.94
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.7969 (One-sided p-value) · Risk difference (rd): 7.94 · 90% CI -7.79 to 23.68
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1120 (One-sided p-value) · Risk difference (rd): -11.09 · 90% CI -26.09 to 3.91
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.5021 (One-sided p-value) · Risk difference (rd): 0.05 · 90% CI -15.06 to 15.16
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6197 (One-sided p-value) · Risk difference (rd): 2.83 · 90% CI -12.46 to 18.12
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1003 (One-sided p-value) · Risk difference (rd): -11.30 · 90% CI -25.81 to 3.22
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.5070 (One-sided p-value) · Risk difference (rd): 0.16 · 90% CI -14.50 to 14.81
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.5283 (One-sided p-value) · Risk difference (rd): 0.67 · 90% CI -14.74 to 16.08
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0431 (One-sided p-value) · Risk difference (rd): -15.31 · 90% CI -29.98 to -0.63
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.2395 (One-sided p-value) · Risk difference (rd): -6.39 · 90% CI -21.22 to 8.45
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6054 (One-sided p-value) · Risk difference (rd): 2.57 · 90% CI -13.25 to 18.39
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0106 (One-sided p-value) · Risk difference (rd): -21.54 · 90% CI -36.91 to -6.17
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.0890 (One-sided p-value) · Risk difference (rd): -12.54 · 90% CI -27.84 to 2.77
SecondaryLeast Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)

Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Percent change
Least Squares Mean of Percent Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 -ANCOVA (FAS With Baseline ≥3, MI)
Percent changePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1-Average Pain-2.47 (-9.45 to 4.51)-8.64 (-16.06 to -1.22)-13.53 (-20.29 to -6.77)-8.81 (-16.53 to -1.10)
Week 2-Average Pain-11.24 (-19.66 to -2.83)-13.39 (-22.42 to -4.37)-21.59 (-29.80 to -13.38)-13.49 (-22.78 to -4.20)
Week 4-Average Pain-24.04 (-34.14 to -13.94)-16.00 (-26.79 to -5.21)-33.01 (-42.90 to -23.13)-18.67 (-29.57 to -7.77)
Week 6-Average Pain-28.65 (-39.19 to -18.10)-14.86 (-26.11 to -3.61)-38.04 (-48.30 to -27.77)-22.60 (-34.04 to -11.16)
Week 8-Average Pain-30.75 (-41.20 to -20.31)-21.78 (-32.86 to -10.70)-39.59 (-49.80 to -29.39)-22.11 (-33.48 to -10.75)
Week 12-Average Pain-30.85 (-40.83 to -20.87)-28.50 (-39.14 to -17.87)-45.24 (-54.97 to -35.50)-30.42 (-41.28 to -19.57)
Week 16-Average Pain-27.83 (-37.98 to -17.69)-23.80 (-34.41 to -13.18)-46.21 (-56.05 to -36.37)-31.92 (-42.93 to -20.91)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.1505 (One-sided p-value) · Risk difference (rd): -6.17 · 90% CI -15.98 to 3.64
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0233 (One-sided p-value) · Risk difference (rd): -11.06 · 90% CI -20.19 to -1.92
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1423 (One-sided p-value) · Risk difference (rd): -6.34 · 90% CI -16.09 to 3.41
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.3827 (One-sided p-value) · Risk difference (rd): -2.15 · 90% CI -14.00 to 9.70
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0624 (One-sided p-value) · Risk difference (rd): -10.35 · 90% CI -21.44 to 0.74
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.3771 (One-sided p-value) · Risk difference (rd): -2.25 · 90% CI -14.04 to 9.55
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.8247 (One-sided p-value) · Risk difference (rd): 8.04 · 90% CI -6.13 to 22.21
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1337 (One-sided p-value) · Risk difference (rd): -8.97 · 90% CI -22.28 to 4.33
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.7357 (One-sided p-value) · Risk difference (rd): 5.37 · 90% CI -8.65 to 19.39
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.9377 (One-sided p-value) · Risk difference (rd): 13.78 · 90% CI -0.98 to 28.55
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1332 (One-sided p-value) · Risk difference (rd): -9.39 · 90% CI -23.29 to 4.51
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.7514 (One-sided p-value) · Risk difference (rd): 6.05 · 90% CI -8.60 to 20.70
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.8433 (One-sided p-value) · Risk difference (rd): 8.97 · 90% CI -5.67 to 23.62
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1461 (One-sided p-value) · Risk difference (rd): -8.84 · 90% CI -22.64 to 4.96
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.8364 (One-sided p-value) · Risk difference (rd): 8.64 · 90% CI -5.86 to 23.15
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6085 (One-sided p-value) · Risk difference (rd): 2.35 · 90% CI -11.68 to 16.37
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0365 (One-sided p-value) · Risk difference (rd): -14.38 · 90% CI -27.58 to -1.19
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.5201 (One-sided p-value) · Risk difference (rd): 0.43 · 90% CI -13.50 to 14.36
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6813 (One-sided p-value) · Risk difference (rd): 4.04 · 90% CI -10.05 to 18.12
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0128 (One-sided p-value) · Risk difference (rd): -18.38 · 90% CI -31.91 to -4.84
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.3181 (One-sided p-value) · Risk difference (rd): -4.09 · 90% CI -18.30 to 10.12
SecondaryLeast Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)

Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Percent change
Least Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, at Worst, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)
Percent changePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1-Pain at its Worst-0.23 (-0.59 to 0.13)-0.54 (-0.91 to -0.16)-0.68 (-1.03 to -0.33)-0.71 (-1.09 to -0.33)
Week 2-Pain at its Worst-0.52 (-0.98 to -0.05)-0.84 (-1.32 to -0.36)-1.07 (-1.52 to -0.62)-0.91 (-1.40 to -0.43)
Week 4-Pain at its Worst-1.22 (-1.74 to -0.70)-1.15 (-1.68 to -0.61)-1.67 (-2.17 to -1.16)-1.19 (-1.74 to -0.65)
Week 6-Pain at its Worst-1.55 (-2.10 to -1.01)-1.06 (-1.62 to -0.50)-1.97 (-2.50 to -1.45)-1.43 (-2.00 to -0.87)
Week 8-Pain at its Worst-1.56 (-2.11 to -1.01)-1.40 (-1.97 to -0.83)-1.95 (-2.48 to -1.41)-1.43 (-2.01 to -0.86)
Week 12-Pain at its Worst-1.80 (-2.35 to -1.26)-1.74 (-2.30 to -1.18)-2.37 (-2.89 to -1.84)-1.80 (-2.37 to -1.23)
Week 16-Pain at its Worst-1.44 (-2.00 to -0.89)-1.35 (-1.91 to -0.80)-2.51 (-3.04 to -1.98)-2.01 (-2.58 to -1.44)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.1536 (One-sided p-value) · Risk difference (rd): -0.31 · 90% CI -0.80 to 0.19
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0581 (One-sided p-value) · Risk difference (rd): -0.45 · 90% CI -0.93 to 0.02
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.0532 (One-sided p-value) · Risk difference (rd): -0.48 · 90% CI -0.98 to 0.01
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.2007 (One-sided p-value) · Risk difference (rd): -0.32 · 90% CI -0.95 to 0.31
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0694 (One-sided p-value) · Risk difference (rd): -0.55 · 90% CI -1.16 to 0.06
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1509 (One-sided p-value) · Risk difference (rd): -0.39 · 90% CI -1.02 to 0.23
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.5663 (One-sided p-value) · Risk difference (rd): 0.07 · 90% CI -0.64 to 0.78
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1396 (One-sided p-value) · Risk difference (rd): -0.45 · 90% CI -1.13 to 0.23
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.5227 (One-sided p-value) · Risk difference (rd): 0.02 · 90% CI -0.69 to 0.74
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.8656 (One-sided p-value) · Risk difference (rd): 0.50 · 90% CI -0.24 to 1.24
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1671 (One-sided p-value) · Risk difference (rd): -0.42 · 90% CI -1.13 to 0.29
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.6063 (One-sided p-value) · Risk difference (rd): 0.12 · 90% CI -0.62 to 0.86
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6402 (One-sided p-value) · Risk difference (rd): 0.16 · 90% CI -0.59 to 0.92
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1916 (One-sided p-value) · Risk difference (rd): -0.38 · 90% CI -1.11 to 0.34
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.6119 (One-sided p-value) · Risk difference (rd): 0.13 · 90% CI -0.62 to 0.88
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.5568 (One-sided p-value) · Risk difference (rd): 0.06 · 90% CI -0.68 to 0.80
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0976 (One-sided p-value) · Risk difference (rd): -0.56 · 90% CI -1.27 to 0.15
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.5001 (One-sided p-value) · Risk difference (rd): 0.00 · 90% CI -0.74 to 0.74
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.5810 (One-sided p-value) · Risk difference (rd): 0.09 · 90% CI -0.65 to 0.83
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0079 (One-sided p-value) · Risk difference (rd): -1.07 · 90% CI -1.80 to -0.34
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1068 (One-sided p-value) · Risk difference (rd): -0.57 · 90% CI -1.31 to 0.18
SecondaryLeast Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)

Patient Global Assessment Skin Pain Numeric Rating Scale was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). These two concepts were measured within the same instrument, but were scored separately. There was no composite score for this endpoint. The higher the score, the worse the outcomes, ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Subscales were not combined. The ANCOVA model was fitted. Confidence interval (CI) was calculated using Blyth-Still-Casella method.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Percent change
Least Squares Mean of Change From Baseline in PGA Skin Pain Numeric Rating Scale, on Average, at Weeks 1, 2, 4, 6, 8, 12 and 16 - ANCOVA (FAS, MI)
Percent changePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1-Average Pain-0.19 (-0.53 to 0.15)-0.44 (-0.79 to -0.09)-0.62 (-0.96 to -0.29)-0.50 (-0.86 to -0.14)
Week 2-Average Pain-0.49 (-0.90 to -0.07)-0.77 (-1.20 to -0.34)-0.94 (-1.35 to -0.54)-0.66 (-1.09 to -0.22)
Week 4-Average Pain-1.22 (-1.72 to -0.73)-1.10 (-1.61 to -0.60)-1.73 (-2.21 to -1.25)-1.02 (-1.53 to -0.51)
Week 6-Average Pain-1.49 (-2.01 to -0.98)-0.98 (-1.52 to -0.45)-1.92 (-2.42 to -1.42)-1.29 (-1.83 to -0.75)
Week 8-Average Pain-1.56 (-2.09 to -1.02)-1.35 (-1.89 to -0.80)-1.88 (-2.39 to -1.37)-1.30 (-1.85 to -0.74)
Week 12-Average Pain-1.68 (-2.20 to -1.17)-1.71 (-2.23 to -1.18)-2.25 (-2.75 to -1.76)-1.53 (-2.06 to -1.00)
Week 16-Average Pain-1.40 (-1.93 to -0.87)-1.37 (-1.89 to -0.84)-2.29 (-2.79 to -1.79)-1.77 (-2.31 to -1.23)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.1898 (One-sided p-value) · Risk difference (rd): -0.25 · 90% CI -0.72 to 0.22
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0562 (One-sided p-value) · Risk difference (rd): -0.43 · 90% CI -0.88 to 0.02
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1382 (One-sided p-value) · Risk difference (rd): -0.31 · 90% CI -0.78 to 0.16
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.2039 (One-sided p-value) · Risk difference (rd): -0.28 · 90% CI -0.85 to 0.28
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0855 (One-sided p-value) · Risk difference (rd): -0.45 · 90% CI -1.00 to 0.09
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.3089 (One-sided p-value) · Risk difference (rd): -0.17 · 90% CI -0.74 to 0.39
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6124 (One-sided p-value) · Risk difference (rd): 0.12 · 90% CI -0.55 to 0.79
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1003 (One-sided p-value) · Risk difference (rd): -0.50 · 90% CI -1.15 to 0.14
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.6875 (One-sided p-value) · Risk difference (rd): 0.20 · 90% CI -0.47 to 0.87
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.8833 (One-sided p-value) · Risk difference (rd): 0.51 · 90% CI -0.19 to 1.21
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.1502 (One-sided p-value) · Risk difference (rd): -0.43 · 90% CI -1.11 to 0.25
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.6788 (One-sided p-value) · Risk difference (rd): 0.20 · 90% CI -0.50 to 0.90
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.6835 (One-sided p-value) · Risk difference (rd): 0.21 · 90% CI -0.51 to 0.94
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.2237 (One-sided p-value) · Risk difference (rd): -0.32 · 90% CI -1.02 to 0.38
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.7234 (One-sided p-value) · Risk difference (rd): 0.26 · 90% CI -0.46 to 0.98
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.4773 (One-sided p-value) · Risk difference (rd): -0.02 · 90% CI -0.72 to 0.67
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0818 (One-sided p-value) · Risk difference (rd): -0.57 · 90% CI -1.25 to 0.10
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.6397 (One-sided p-value) · Risk difference (rd): 0.15 · 90% CI -0.55 to 0.85
  • Placebo vs PF-06650833 400mg QD · ANCOVA · p = 0.5321 (One-sided p-value) · Risk difference (rd): 0.03 · 90% CI -0.67 to 0.74
  • Placebo vs PF-06700841 45mg QD · ANCOVA · p = 0.0167 (One-sided p-value) · Risk difference (rd): -0.89 · 90% CI -1.59 to -0.20
  • Placebo vs PF-06826647 400mg QD · ANCOVA · p = 0.1963 (One-sided p-value) · Risk difference (rd): -0.37 · 90% CI -1.09 to 0.34
SecondaryPercentage of Participants Achieving Erythema Response Among Participants With Baseline Erythema Score ≥2 in at Least 1 Region at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS, NRI)

Erythema response was defined as achieving erythema score of 1 or 0 in all affected anatomic regions among participants who had an erythema score of 2 or more in at least 1 anatomic region at baseline. NRI for missing values which were related to withdrawal and all other events except for COVID-19. A four-point ordinal scale ranging was used: 0 (no redness), 1 (faint but discernible pink coloration), 2 (moderate red coloration), and 3 (very red or bright red coloration).

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Erythema Response Among Participants With Baseline Erythema Score ≥2 in at Least 1 Region at Weeks 1, 2, 4, 6, 8, 12 and 16 - MR (FAS, NRI)
Percentage of participantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 16.5 (2.4 to 15.8)4.7 (1.2 to 13.2)8.7 (3.8 to 17.6)13.6 (6.1 to 24.3)
Week 210.9 (5.4 to 21.3)20.9 (12.3 to 33.3)17.8 (9.2 to 29.7)18.2 (9.4 to 30.0)
Week 413.3 (6.0 to 23.7)20.9 (12.3 to 33.3)28.3 (17.6 to 40.4)18.2 (9.4 to 30.0)
Week 613.0 (5.8 to 23.2)27.9 (17.0 to 39.9)23.9 (15.1 to 35.0)23.3 (13.2 to 35.5)
Week 815.2 (8.2 to 25.5)25.6 (16.3 to 37.7)28.3 (17.6 to 40.4)23.3 (13.2 to 35.5)
Week 1215.2 (8.2 to 25.5)23.3 (13.2 to 35.5)30.4 (20.4 to 43.4)18.6 (9.6 to 30.2)
Week 1613.0 (5.8 to 23.2)16.3 (8.8 to 27.0)28.3 (17.6 to 40.4)18.6 (9.6 to 30.2)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -2.2 · 90% CI -10.3 to 6.0
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 2.0 · 90% CI -7.3 to 11.3
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 6.8 · 90% CI -3.9 to 17.4
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 10.7 · 90% CI -2.0 to 23.4
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 7.6 · 90% CI -4.5 to 19.7
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 7.5 · 90% CI -4.6 to 19.6
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 7.4 · 90% CI -5.7 to 20.5
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 15.1 · 90% CI 1.4 to 28.7
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 4.8 · 90% CI -8.0 to 17.5
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 14.3 · 90% CI 0.7 to 28.0
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 10.9 · 90% CI -2.2 to 24.0
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 10.6 · 90% CI -2.6 to 23.9
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.1162 (One-sided p-value) · Risk difference (rd): 10.1 · 90% CI -3.6 to 23.9P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0642 (One-sided p-value) · Risk difference (rd): 13.1 · 90% CI -0.8 to 27.0P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.1664 (One-sided p-value) · Risk difference (rd): 8.1 · 90% CI -5.7 to 21.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.1882 (One-sided p-value) · Risk difference (rd): 7.2 · 90% CI -6.1 to 20.5P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0423 (One-sided p-value) · Risk difference (rd): 14.9 · 90% CI 1.1 to 28.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.3396 (One-sided p-value) · Risk difference (rd): 3.3 · 90% CI -9.7 to 16.3P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06650833 400mg QD · MR weighting strategy · p = 0.3584 (One-sided p-value) · Risk difference (rd): 2.7 · 90% CI -9.4 to 14.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06700841 45mg QD · MR weighting strategy · p = 0.0367 (One-sided p-value) · Risk difference (rd): 14.9 · 90% CI 1.5 to 28.3P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
  • Placebo vs PF-06826647 400mg QD · MR weighting strategy · p = 0.2486 (One-sided p-value) · Risk difference (rd): 5.2 · 90% CI -7.4 to 17.8P-value method for risk difference (RD) was minimum risk (MR) weighting strategy by Mehrotra and Railkar (2000).
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (All Causalities)

The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (All Causalities)
ParticipantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Participants with adverse events23263029
Participants with serious adverse events0202
Participants with severe adverse events1214
Participants discontinued from study due to adverse events0116
Participants discontinued study drug due to AE and continued Study1221
Participants with temporary discontinuation due to adverse events2135
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (Treatment Related)

The treatment-emergent AEs (TEAEs) were considered as an adverse event that started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time was flagged as TEAEs.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (Treatment Related)
ParticipantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Participants with adverse events7101216
Participants with serious adverse events0101
Participants with severe adverse events0103
Participants discontinued from study due to adverse events0114
Participants discontinued study drug due to AE and continued Study1120
Participants with temporary discontinuation due to adverse events1102
SecondaryNumber of Participants With Incidence of Post-baseline Vital Signs of Clinical Concern - Increase From Baseline (Safety Analysis Set)

The vital signs were measured included temperature (Oral, Tympanic, Axillary or Temporal), pulse rate (beats/min) and blood pressure (mmHg).

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Post-baseline Vital Signs of Clinical Concern - Increase From Baseline (Safety Analysis Set)
ParticipantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Supine Diastolic Blood Pressure (MMHG): Change >= 20mmHg increase2124
Supine Systolic Blood Pressure (MMHG): Change >= 30mmHg increase1124
SecondaryNumber of Participants With Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) (Safety Analysis Set)

Laboratory test abnormalities included hematology, chemistry, urinalysis and biomarker.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) (Safety Analysis Set)
ParticipantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Hematology: hemoglobin (g/dL) <0.8x lower limit of normal (LLN)1040
Hematology: Hematocrit (%) <0.8x LLN0010
Hematology: Erythrocytes (10^6/mm^3) <0.8x LLN0031
Hematology: Ery. Mean Corpuscular Volume (um^3) <0.9x LLN1210
Hematology: Ery. Mean Corpuscular Volume (um^3) >1.1x ULN0211
Hematology: Ery. Mean Corpuscular Hemoglobin (pg/cell) <0.9x LLN5575
Hematology: Ery. Mean Corpuscular Hemoglobin (pg/cell) >1.1x ULN0000
Hematology: Ery. Mean Corpuscular HGB Concentration (g/dL) <0.9x LLN6366
Hematology: Ery. Mean Corpuscular HGB Concentration (g/dL) >1.1x ULN0000
Hematology: Mean Platelet Volume (fL) <0.9x LLN0002
Hematology: Mean Platelet Volume (fL) >1.1x ULN1000
Hematology: Platelets (10^3/mm^3) <0.5x LLN0001
Hematology: Platelets (10^3/mm^3) >1.75x ULN0013
Hematology: Leukocytes (10^3/mm^3) <0.6x LLN0013
Hematology: Leukocytes (10^3/mm^3) >1.5x ULN4110
Hematology: Lymphocytes (10^3/mm^3) <0.8x LLN1013
Hematology: Lymphocytes (10^3/mm^3) >1.2x ULN5274
Hematology: Neutrophils (10^3/mm^3) <0.8x LLN0038
Hematology: Neutrophils (10^3/mm^3) >1.2x ULN8364
Hematology: Basophils (10^3/mm^3) >1.2x ULN0000
Hematology: Eosinophils (10^3/mm^3) >1.2x ULN0100
Hematology: Monocytes (10^3/mm^3) >1.2x ULN2000
Clinical Chemistry: Bilirubin (mg/dL) >1.5x ULN0000
Clinical Chemistry: Aspartate Aminotransferase (U/L) >3.0x ULN0110
Clinical Chemistry: Alanine Aminotransferase (U/L) >3.0x ULN0121
Clinical Chemistry: Alkaline Phosphatase (U/L) >3.0x ULN0000
Clinical Chemistry: Protein (g/dL) <0.8x LLN0000
Clinical Chemistry: Protein (g/dL) >1.2x ULN0000
Clinical Chemistry: Albumin (g/dL) <0.8x LLN0000
Clinical Chemistry: Albumin (g/dL) >1.2x ULN0000
Clinical Chemistry: Urea Nitrogen (mg/dL) >1.3x ULN0102
Clinical Chemistry: Creatinine (mg/dL) >1.3x ULN0010
Clinical Chemistry: Urate (mg/dL) >1.2x ULN3346
Clinical Chemistry: Cholesterol (mg/dL) >1.3x ULN2142
Clinical Chemistry: HDL Cholesterol (mg/dL) <0.8x LLN10665
Clinical Chemistry: LDL Cholesterol (mg/dL) >1.2x ULN1132
Clinical Chemistry: Triglycerides (mg/dL) >1.3x ULN5467
Clinical Chemistry: Sodium (mEq/L) <0.95x LLN0000
Clinical Chemistry: Sodium (mEq/L) >1.05x ULN0000
Clinical Chemistry: Potassium (mEq/L) <0.9x LLN1110
Clinical Chemistry: Potassium (mEq/L) >1.1x ULN1202
Clinical Chemistry: Chloride (mEq/L) <0.9x LLN0000
Clinical Chemistry: Chloride (mEq/L) >1.1x ULN0000
Clinical Chemistry: Calcium (mg/dL) <0.9x LLN0200
Clinical Chemistry: Calcium (mg/dL) >1.1x ULN0000
Clinical Chemistry: Bicarbonate (mEq/L) <0.9x LLN1010213
Clinical Chemistry: Bicarbonate (mEq/L) >1.1x ULN0100
Clinical Chemistry: Glucose (mg/dL) <0.6x LLN0000
Clinical Chemistry: Glucose (mg/dL) >1.5x ULN1213
Clinical Chemistry: Creatine Kinase (U/L) >2.0x ULN621820
Clinical Chemistry: Glucose -FASTING (mg/dL) <0.6x LLN0000
Clinical Chemistry: Glucose -FASTING (mg/dL) >1.5x ULN4535
Urinalysis: pH <4.50000
Urinalysis: pH >82125
Urinalysis: URINE Glucose (mg/dL) ≥14624
Urinalysis: Ketones (mg/dL) ≥196812
Urinalysis: URINE Protein (mg/dL) ≥132302932
Urinalysis: URINE Hemoglobin ≥12391610
Urinalysis: Urobilinogen (EU/dL) ≥13475
Urinalysis: URINE Bilirubin ≥10000
Urinalysis: Nitrite ≥13463
Urinalysis: Leukocyte Esterase ≥110596
Urinalysis: URINE Erythrocytes (/HPF) ≥204251
Urinalysis: Granular Casts (/LPF) >10000
Urinalysis: Hyaline Casts (/LPF) >11112
Urinalysis: RBC Casts (/LPF) >10000
Urinalysis: WBC Casts (/LPF) >10000
Urinalysis: Bacteria (/HPF) >206654
Biomarker: C Reactive Protein (mg/dL) >1.1x ULN37293730
SecondaryNumber of Participants With Incidence of Post-baseline Electrocardiogram (ECG) Values of Clinical Concern (Safety Analysis Set)

ECG parameters included QT interval, QTc interval, PR interval, and QRS complex.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Post-baseline Electrocardiogram (ECG) Values of Clinical Concern (Safety Analysis Set)
ParticipantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
PR INTERVAL, SINGLE BEAT (MSEC): Value>2800000
QRS DURATION, SINGLE BEAT (MSEC): Value>1202031
QT INTERVAL, SINGLE BEAT (MSEC): Value>5000000
QTCB INTERVAL, SINGLE BEAT (MSEC): 450<Value<=4801212167
QTCB INTERVAL, SINGLE BEAT (MSEC): 480<Value<5001021
QTCB INTERVAL, SINGLE BEAT (MSEC): Value>=5001010
QTCB INTERVAL, SINGLE BEAT (MSEC): 30<=Chg<=60912136
QTCB INTERVAL, SINGLE BEAT (MSEC): Chg>600110
QTCF INTERVAL, SINGLE BEAT (MSEC): 450<Value<=4802262
QTCF INTERVAL, SINGLE BEAT (MSEC): 480<Value<5001010
QTCF INTERVAL, SINGLE BEAT (MSEC): Value>=5000000
QTCF INTERVAL, SINGLE BEAT (MSEC): 30<=Chg<=605672
QTCF INTERVAL, SINGLE BEAT (MSEC): Chg>600110
SecondaryLeast Squares Mean of Absolute Score in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - Mixed Effect Model Repeated Measurement (MMRM) (FAS, OBS)

The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Units on a scale
Least Squares Mean of Absolute Score in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - Mixed Effect Model Repeated Measurement (MMRM) (FAS, OBS)
Units on a scalePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1-HSS0101-Pain At It's Worst5.67 (5.33 to 6.01)5.47 (5.13 to 5.82)5.19 (4.86 to 5.52)5.25 (4.90 to 5.60)
Week 2-HSS0101-Pain At It's Worst5.39 (4.95 to 5.84)5.10 (4.63 to 5.57)4.69 (4.25 to 5.12)4.83 (4.36 to 5.29)
Week 4-HSS0101-Pain At It's Worst4.75 (4.21 to 5.29)5.01 (4.42 to 5.59)4.36 (3.83 to 4.89)4.69 (4.11 to 5.26)
Week 6-HSS0101-Pain At It's Worst4.39 (3.80 to 4.98)5.02 (4.38 to 5.65)4.20 (3.61 to 4.79)4.60 (3.96 to 5.24)
Week 8-HSS0101-Pain At It's Worst4.46 (3.83 to 5.09)4.70 (4.02 to 5.37)4.14 (3.51 to 4.77)4.91 (4.22 to 5.60)
Week 12-HSS0101-Pain At It's Worst4.28 (3.63 to 4.92)4.44 (3.73 to 5.15)3.60 (2.95 to 4.24)4.35 (3.65 to 5.06)
Week 16-HSS0101-Pain At It's Worst4.77 (4.06 to 5.48)4.86 (4.09 to 5.62)3.53 (2.83 to 4.22)3.87 (3.11 to 4.62)
Week 1-HSS0102-Tenderness At It's Worst5.66 (5.33 to 5.99)5.66 (5.32 to 6.00)5.37 (5.05 to 5.69)5.35 (5.01 to 5.69)
Week 2-HSS0102-Tenderness At It's Worst5.46 (5.05 to 5.87)5.24 (4.81 to 5.67)5.06 (4.66 to 5.46)5.00 (4.57 to 5.43)
Week 4-HSS0102-Tenderness At It's Worst4.85 (4.33 to 5.38)5.07 (4.50 to 5.65)4.61 (4.09 to 5.13)4.75 (4.18 to 5.31)
Week 6-HSS0102-Tenderness At It's Worst4.65 (4.06 to 5.23)5.12 (4.49 to 5.75)4.41 (3.82 to 5.00)4.65 (4.02 to 5.29)
Week 8-HSS0102-Tenderness At It's Worst4.69 (4.08 to 5.31)4.78 (4.13 to 5.44)4.45 (3.84 to 5.06)5.04 (4.37 to 5.71)
Week 12-HSS0102-Tenderness At It's Worst4.40 (3.78 to 5.01)4.45 (3.77 to 5.13)3.90 (3.29 to 4.52)4.41 (3.74 to 5.09)
Week 16-HSS0102-Tenderness At It's Worst5.04 (4.36 to 5.73)5.08 (4.35 to 5.82)3.80 (3.14 to 4.47)3.93 (3.20 to 4.66)
Week 1-HSS0103-Swelling At It's Worst5.53 (5.20 to 5.86)5.43 (5.09 to 5.77)5.30 (4.98 to 5.62)5.07 (4.73 to 5.40)
Week 2-HSS0103-Swelling At It's Worst5.17 (4.76 to 5.58)4.93 (4.50 to 5.36)4.70 (4.31 to 5.10)4.77 (4.35 to 5.20)
Week 4-HSS0103-Swelling At It's Worst4.57 (4.07 to 5.07)4.73 (4.19 to 5.27)4.40 (3.91 to 4.89)4.66 (4.12 to 5.19)
Week 6-HSS0103-Swelling At It's Worst4.36 (3.79 to 4.94)5.06 (4.44 to 5.68)4.35 (3.77 to 4.92)4.60 (3.97 to 5.22)
Week 8-HSS0103-Swelling At It's Worst4.38 (3.81 to 4.96)4.67 (4.06 to 5.28)4.38 (3.81 to 4.96)4.88 (4.26 to 5.51)
Week 12-HSS0103-Swelling At It's Worst4.34 (3.75 to 4.93)4.40 (3.75 to 5.06)3.87 (3.28 to 4.47)4.30 (3.65 to 4.95)
Week 16-HSS0103-Swelling At It's Worst4.79 (4.12 to 5.45)5.02 (4.30 to 5.73)3.73 (3.08 to 4.37)3.77 (3.06 to 4.47)
Week 1-HSS0104-Tiredness At It's Worst5.55 (5.24 to 5.85)5.71 (5.40 to 6.02)4.98 (4.68 to 5.27)5.63 (5.32 to 5.94)
Week 2-HSS0104-Tiredness At It's Worst5.10 (4.69 to 5.51)5.16 (4.73 to 5.58)4.66 (4.26 to 5.06)5.36 (4.94 to 5.79)
Week 4-HSS0104-Tiredness At It's Worst5.05 (4.56 to 5.54)4.93 (4.41 to 5.46)4.24 (3.76 to 4.72)4.91 (4.39 to 5.42)
Week 6-HSS0104-Tiredness At It's Worst4.77 (4.23 to 5.32)4.81 (4.23 to 5.40)4.25 (3.71 to 4.80)4.89 (4.30 to 5.48)
Week 8-HSS0104-Tiredness At It's Worst4.86 (4.31 to 5.41)4.69 (4.11 to 5.28)4.32 (3.78 to 4.87)4.97 (4.38 to 5.56)
Week 12-HSS0104-Tiredness At It's Worst4.80 (4.21 to 5.38)4.46 (3.81 to 5.10)3.99 (3.40 to 4.57)4.95 (4.30 to 5.59)
Week 16-HSS0104-Tiredness At It's Worst4.59 (3.96 to 5.22)4.81 (4.14 to 5.49)4.03 (3.42 to 4.65)4.68 (4.01 to 5.36)
Week 1-HSS0105-Bothered By Appearance HS Lesion7.38 (7.08 to 7.69)7.43 (7.12 to 7.75)7.06 (6.76 to 7.36)7.37 (7.05 to 7.68)
Week 2-HSS0105-Bothered By Appearance HS Lesion7.34 (6.96 to 7.72)7.24 (6.84 to 7.64)6.55 (6.18 to 6.92)6.99 (6.59 to 7.38)
Week 4-HSS0105-Bothered By Appearance HS Lesion6.94 (6.48 to 7.41)7.26 (6.77 to 7.76)6.00 (5.54 to 6.46)6.65 (6.16 to 7.15)
Week 6-HSS0105-Bothered By Appearance HS Lesion6.69 (6.18 to 7.21)7.24 (6.69 to 7.79)6.00 (5.49 to 6.52)6.59 (6.04 to 7.15)
Week 8-HSS0105-Bothered By Appearance HS Lesion6.98 (6.42 to 7.53)6.82 (6.23 to 7.41)5.86 (5.31 to 6.42)6.67 (6.07 to 7.28)
Week 12-HSS0105-Bothered By Appearance HS Lesion6.46 (5.84 to 7.07)6.51 (5.84 to 7.17)5.59 (4.98 to 6.20)6.58 (5.91 to 7.24)
Week 16-HSS0105-Bothered By Appearance HS Lesion6.37 (5.69 to 7.05)6.77 (6.04 to 7.50)5.43 (4.76 to 6.09)6.37 (5.64 to 7.09)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.20 · 90% CI -0.69 to 0.29
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.48 · 90% CI -0.96 to -0.01
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.42 · 90% CI -0.91 to 0.06
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.30 · 90% CI -0.95 to 0.35
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.71 · 90% CI -1.33 to -0.08
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.57 · 90% CI -1.21 to 0.08
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.26 · 90% CI -0.54 to 1.05
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.39 · 90% CI -1.15 to 0.37
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.06 · 90% CI -0.85 to 0.73
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.62 · 90% CI -0.24 to 1.49
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.19 · 90% CI -1.03 to 0.64
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.21 · 90% CI -0.66 to 1.08
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.24 · 90% CI -0.69 to 1.16
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.32 · 90% CI -1.21 to 0.57
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.44 · 90% CI -0.49 to 1.38
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.16 · 90% CI -0.79 to 1.12
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.68 · 90% CI -1.59 to 0.23
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.08 · 90% CI -0.88 to 1.03
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.08 · 90% CI -0.96 to 1.13
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.25 · 90% CI -2.24 to -0.25
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.91 · 90% CI -1.95 to 0.13
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.01 · 90% CI -0.47 to 0.48
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.28 · 90% CI -0.75 to 0.18
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.31 · 90% CI -0.78 to 0.17
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.22 · 90% CI -0.81 to 0.38
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.40 · 90% CI -0.97 to 0.18
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.46 · 90% CI -1.05 to 0.14
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.22 · 90% CI -0.56 to 1.00
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.25 · 90% CI -0.99 to 0.49
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.11 · 90% CI -0.88 to 0.67
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.48 · 90% CI -0.38 to 1.34
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.23 · 90% CI -1.06 to 0.60
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.01 · 90% CI -0.86 to 0.87
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.81 to 0.99
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.25 · 90% CI -1.11 to 0.62
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.35 · 90% CI -0.56 to 1.25
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.05 · 90% CI -0.87 to 0.97
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.49 · 90% CI -1.36 to 0.38
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.02 · 90% CI -0.90 to 0.93
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.04 · 90% CI -0.96 to 1.04
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.24 · 90% CI -2.19 to -0.29
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -1.11 · 90% CI -2.11 to -0.11
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.10 · 90% CI -0.57 to 0.37
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.23 · 90% CI -0.69 to 0.22
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.47 · 90% CI -0.94 to 0.01
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.24 · 90% CI -0.83 to 0.35
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.46 · 90% CI -1.03 to 0.11
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.40 · 90% CI -0.99 to 0.19
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.16 · 90% CI -0.58 to 0.90
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.17 · 90% CI -0.87 to 0.53
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.65 to 0.82
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.70 · 90% CI -0.15 to 1.54
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.02 · 90% CI -0.83 to 0.80
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.23 · 90% CI -0.62 to 1.08
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.29 · 90% CI -0.55 to 1.13
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 0.00 · 90% CI -0.81 to 0.81
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.50 · 90% CI -0.35 to 1.35
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.07 · 90% CI -0.81 to 0.95
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.47 · 90% CI -1.30 to 0.37
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.04 · 90% CI -0.92 to 0.84
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.23 · 90% CI -0.75 to 1.20
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.06 · 90% CI -1.99 to -0.13
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -1.02 · 90% CI -1.99 to -0.05
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.16 · 90% CI -0.27 to 0.59
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.57 · 90% CI -0.99 to -0.15
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.35 to 0.52
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.06 · 90% CI -0.54 to 0.65
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.44 · 90% CI -1.01 to 0.13
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.26 · 90% CI -0.33 to 0.85
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.12 · 90% CI -0.83 to 0.60
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.81 · 90% CI -1.49 to -0.12
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.14 · 90% CI -0.86 to 0.57
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.04 · 90% CI -0.76 to 0.84
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.52 · 90% CI -1.29 to 0.26
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.12 · 90% CI -0.68 to 0.92
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.17 · 90% CI -0.96 to 0.63
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.53 · 90% CI -1.31 to 0.24
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.11 · 90% CI -0.69 to 0.92
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.34 · 90% CI -1.21 to 0.53
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.81 · 90% CI -1.64 to 0.02
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.15 · 90% CI -0.72 to 1.02
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.22 · 90% CI -0.70 to 1.15
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.56 · 90% CI -1.44 to 0.32
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.83 to 1.01
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.05 · 90% CI -0.39 to 0.49
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.32 · 90% CI -0.75 to 0.10
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.02 · 90% CI -0.46 to 0.42
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.10 · 90% CI -0.65 to 0.45
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.80 · 90% CI -1.33 to -0.27
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.36 · 90% CI -0.91 to 0.19
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.32 · 90% CI -0.36 to 1.00
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.94 · 90% CI -1.59 to -0.29
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.29 · 90% CI -0.97 to 0.39
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.55 · 90% CI -0.20 to 1.30
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.69 · 90% CI -1.41 to 0.04
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.10 · 90% CI -0.85 to 0.66
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.15 · 90% CI -0.96 to 0.66
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.11 · 90% CI -1.89 to -0.33
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.30 · 90% CI -1.13 to 0.52
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.05 · 90% CI -0.86 to 0.95
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.87 · 90% CI -1.73 to -0.01
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.12 · 90% CI -0.78 to 1.03
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.39 · 90% CI -0.60 to 1.39
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.95 · 90% CI -1.90 to 0.00
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.01 · 90% CI -1.00 to 0.99
SecondaryLeast Squares Mean of Change From Baseline in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - MMRM (FAS, OBS)

The Hidradenitis Suppurativa Symptom Items were 5 single items that assessed patient self-reported symptoms related to HS. The participants were asked to rate each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom. The symptoms assessed include: pain, tenderness, swelling, tiredness, and bother of lesion appearance. The higher the score, the worse the outcomes, ranging from 0 indicating no symptom experience and 10 indicating the worst possible symptom. These concepts were scored separately, and were not combined into a composite score. When using mixed effect model repeated measurement (MMRM) analysis, only observed data were used and missing data were not imputed.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Least squares mean · Units on a scale
Least Squares Mean of Change From Baseline in Hidradenitis Suppurativa (HS) Symptom Items up to Week 16 - MMRM (FAS, OBS)
Units on a scalePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 1-HSS0101-Pain At It's Worst-0.19 (-0.53 to 0.15)-0.39 (-0.74 to -0.04)-0.67 (-1.00 to -0.34)-0.61 (-0.96 to -0.26)
Week 2-HSS0101-Pain At It's Worst-0.47 (-0.92 to -0.02)-0.77 (-1.24 to -0.30)-1.18 (-1.61 to -0.74)-1.04 (-1.50 to -0.57)
Week 4-HSS0101-Pain At It's Worst-1.12 (-1.66 to -0.58)-0.86 (-1.44 to -0.27)-1.51 (-2.04 to -0.98)-1.18 (-1.76 to -0.60)
Week 6-HSS0101-Pain At It's Worst-1.47 (-2.06 to -0.88)-0.85 (-1.48 to -0.21)-1.66 (-2.26 to -1.07)-1.27 (-1.91 to -0.63)
Week 8-HSS0101-Pain At It's Worst-1.40 (-2.03 to -0.77)-1.17 (-1.84 to -0.49)-1.72 (-2.35 to -1.09)-0.96 (-1.65 to -0.27)
Week 12-HSS0101-Pain At It's Worst-1.59 (-2.23 to -0.94)-1.42 (-2.13 to -0.72)-2.27 (-2.91 to -1.62)-1.51 (-2.21 to -0.81)
Week 16-HSS0101-Pain At It's Worst-1.09 (-1.80 to -0.38)-1.01 (-1.77 to -0.24)-2.34 (-3.03 to -1.64)-2.00 (-2.75 to -1.24)
Week 1-HSS0102-Tenderness At It's Worst-0.37 (-0.70 to -0.04)-0.36 (-0.70 to -0.02)-0.65 (-0.97 to -0.33)-0.67 (-1.01 to -0.33)
Week 2-HSS0102-Tenderness At It's Worst-0.56 (-0.97 to -0.15)-0.78 (-1.21 to -0.35)-0.96 (-1.36 to -0.56)-1.02 (-1.45 to -0.59)
Week 4-HSS0102-Tenderness At It's Worst-1.17 (-1.70 to -0.64)-0.95 (-1.52 to -0.37)-1.42 (-1.94 to -0.90)-1.28 (-1.84 to -0.71)
Week 6-HSS0102-Tenderness At It's Worst-1.38 (-1.96 to -0.79)-0.90 (-1.53 to -0.27)-1.61 (-2.20 to -1.02)-1.37 (-2.00 to -0.73)
Week 8-HSS0102-Tenderness At It's Worst-1.33 (-1.94 to -0.72)-1.24 (-1.89 to -0.58)-1.58 (-2.19 to -0.96)-0.98 (-1.65 to -0.31)
Week 12-HSS0102-Tenderness At It's Worst-1.63 (-2.24 to -1.01)-1.57 (-2.25 to -0.90)-2.12 (-2.74 to -1.50)-1.61 (-2.28 to -0.93)
Week 16-HSS0102-Tenderness At It's Worst-0.98 (-1.66 to -0.30)-0.94 (-1.67 to -0.20)-2.22 (-2.89 to -1.55)-2.09 (-2.82 to -1.36)
Week 1-HSS0103-Swelling At It's Worst-0.24 (-0.56 to 0.09)-0.34 (-0.67 to 0.00)-0.47 (-0.79 to -0.15)-0.70 (-1.04 to -0.36)
Week 2-HSS0103-Swelling At It's Worst-0.60 (-1.01 to -0.19)-0.84 (-1.27 to -0.41)-1.06 (-1.46 to -0.66)-1.00 (-1.42 to -0.57)
Week 4-HSS0103-Swelling At It's Worst-1.20 (-1.70 to -0.70)-1.04 (-1.58 to -0.50)-1.37 (-1.86 to -0.87)-1.11 (-1.65 to -0.57)
Week 6-HSS0103-Swelling At It's Worst-1.40 (-1.98 to -0.83)-0.71 (-1.33 to -0.09)-1.42 (-2.00 to -0.84)-1.17 (-1.80 to -0.55)
Week 8-HSS0103-Swelling At It's Worst-1.38 (-1.96 to -0.81)-1.10 (-1.71 to -0.48)-1.38 (-1.96 to -0.81)-0.88 (-1.51 to -0.26)
Week 12-HSS0103-Swelling At It's Worst-1.43 (-2.02 to -0.84)-1.36 (-2.02 to -0.71)-1.90 (-2.49 to -1.30)-1.47 (-2.12 to -0.82)
Week 16-HSS0103-Swelling At It's Worst-0.98 (-1.64 to -0.32)-0.75 (-1.47 to -0.04)-2.04 (-2.69 to -1.39)-2.00 (-2.71 to -1.29)
Week 1-HSS0104-Tiredness At It's Worst-0.04 (-0.34 to 0.26)0.12 (-0.19 to 0.43)-0.61 (-0.91 to -0.32)0.04 (-0.26 to 0.35)
Week 2-HSS0104-Tiredness At It's Worst-0.49 (-0.90 to -0.08)-0.43 (-0.86 to -0.01)-0.93 (-1.32 to -0.53)-0.23 (-0.65 to 0.20)
Week 4-HSS0104-Tiredness At It's Worst-0.54 (-1.03 to -0.05)-0.66 (-1.18 to -0.13)-1.35 (-1.83 to -0.87)-0.68 (-1.20 to -0.16)
Week 6-HSS0104-Tiredness At It's Worst-0.82 (-1.36 to -0.27)-0.78 (-1.36 to -0.19)-1.33 (-1.88 to -0.79)-0.70 (-1.29 to -0.11)
Week 8-HSS0104-Tiredness At It's Worst-0.73 (-1.28 to -0.18)-0.90 (-1.48 to -0.31)-1.26 (-1.81 to -0.72)-0.62 (-1.21 to -0.02)
Week 12-HSS0104-Tiredness At It's Worst-0.79 (-1.38 to -0.20)-1.13 (-1.77 to -0.49)-1.60 (-2.19 to -1.02)-0.64 (-1.28 to 0.00)
Week 16-HSS0104-Tiredness At It's Worst-1.00 (-1.63 to -0.37)-0.78 (-1.45 to -0.10)-1.56 (-2.17 to -0.94)-0.90 (-1.58 to -0.23)
Week 1-HSS0105-Bothered By Appearance HS Lesion-0.19 (-0.49 to 0.12)-0.14 (-0.45 to 0.18)-0.51 (-0.81 to -0.21)-0.20 (-0.52 to 0.11)
Week 2-HSS0105-Bothered By Appearance HS Lesion-0.23 (-0.61 to 0.15)-0.33 (-0.73 to 0.07)-1.02 (-1.39 to -0.65)-0.58 (-0.98 to -0.19)
Week 4-HSS0105-Bothered By Appearance HS Lesion-0.63 (-1.09 to -0.16)-0.30 (-0.80 to 0.19)-1.57 (-2.02 to -1.11)-0.92 (-1.41 to -0.42)
Week 6-HSS0105-Bothered By Appearance HS Lesion-0.88 (-1.39 to -0.36)-0.33 (-0.88 to 0.22)-1.56 (-2.08 to -1.05)-0.97 (-1.53 to -0.42)
Week 8-HSS0105-Bothered By Appearance HS Lesion-0.59 (-1.15 to -0.04)-0.75 (-1.34 to -0.15)-1.71 (-2.26 to -1.15)-0.90 (-1.50 to -0.29)
Week 12-HSS0105-Bothered By Appearance HS Lesion-1.11 (-1.73 to -0.50)-1.06 (-1.73 to -0.40)-1.98 (-2.59 to -1.37)-0.99 (-1.66 to -0.33)
Week 16-HSS0105-Bothered By Appearance HS Lesion-1.20 (-1.87 to -0.52)-0.80 (-1.53 to -0.07)-2.14 (-2.81 to -1.48)-1.20 (-1.92 to -0.48)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.20 · 90% CI -0.69 to 0.29
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.48 · 90% CI -0.96 to -0.01
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.42 · 90% CI -0.91 to 0.06
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.30 · 90% CI -0.95 to 0.35
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.71 · 90% CI -1.33 to -0.08
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.57 · 90% CI -1.21 to 0.08
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.26 · 90% CI -0.54 to 1.05
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.39 · 90% CI -1.15 to 0.37
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.06 · 90% CI -0.85 to 0.73
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.62 · 90% CI -0.24 to 1.49
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.19 · 90% CI -1.03 to 0.64
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.21 · 90% CI -0.66 to 1.08
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.24 · 90% CI -0.69 to 1.16
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.32 · 90% CI -1.21 to 0.57
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.44 · 90% CI -0.49 to 1.38
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.16 · 90% CI -0.79 to 1.12
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.68 · 90% CI -1.59 to 0.23
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.08 · 90% CI -0.88 to 1.03
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.08 · 90% CI -0.96 to 1.13
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.25 · 90% CI -2.24 to -0.25
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.91 · 90% CI -1.95 to 0.13
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.01 · 90% CI -0.47 to 0.48
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.28 · 90% CI -0.75 to 0.18
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.31 · 90% CI -0.78 to 0.17
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.22 · 90% CI -0.81 to 0.38
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.40 · 90% CI -0.97 to 0.18
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.46 · 90% CI -1.05 to 0.14
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.22 · 90% CI -0.56 to 1.00
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.25 · 90% CI -0.99 to 0.49
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.11 · 90% CI -0.88 to 0.67
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.48 · 90% CI -0.38 to 1.34
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.23 · 90% CI -1.06 to 0.60
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.01 · 90% CI -0.86 to 0.87
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.81 to 0.99
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.25 · 90% CI -1.11 to 0.62
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.35 · 90% CI -0.56 to 1.25
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.05 · 90% CI -0.87 to 0.97
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.49 · 90% CI -1.36 to 0.38
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.02 · 90% CI -0.90 to 0.93
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.04 · 90% CI -0.96 to 1.04
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.24 · 90% CI -2.19 to -0.29
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -1.11 · 90% CI -2.11 to -0.11
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.10 · 90% CI -0.57 to 0.37
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.23 · 90% CI -0.69 to 0.22
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.47 · 90% CI -0.94 to 0.01
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.24 · 90% CI -0.83 to 0.35
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.46 · 90% CI -1.03 to 0.11
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.40 · 90% CI -0.99 to 0.19
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.16 · 90% CI -0.58 to 0.90
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.17 · 90% CI -0.87 to 0.53
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.65 to 0.82
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.70 · 90% CI -0.15 to 1.54
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.02 · 90% CI -0.83 to 0.80
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.23 · 90% CI -0.62 to 1.08
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.29 · 90% CI -0.55 to 1.13
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 0.00 · 90% CI -0.81 to 0.81
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.50 · 90% CI -0.35 to 1.35
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.07 · 90% CI -0.81 to 0.95
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.47 · 90% CI -1.30 to 0.37
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.04 · 90% CI -0.92 to 0.84
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.23 · 90% CI -0.75 to 1.20
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.06 · 90% CI -1.99 to -0.13
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -1.02 · 90% CI -1.99 to -0.05
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.16 · 90% CI -0.27 to 0.59
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.57 · 90% CI -0.99 to -0.15
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.35 to 0.52
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.06 · 90% CI -0.54 to 0.65
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.44 · 90% CI -1.01 to 0.13
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.26 · 90% CI -0.33 to 0.85
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.12 · 90% CI -0.83 to 0.60
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.81 · 90% CI -1.49 to -0.12
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.14 · 90% CI -0.86 to 0.57
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.04 · 90% CI -0.76 to 0.84
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.52 · 90% CI -1.29 to 0.26
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.12 · 90% CI -0.68 to 0.92
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.17 · 90% CI -0.96 to 0.63
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.53 · 90% CI -1.31 to 0.24
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.11 · 90% CI -0.69 to 0.92
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.34 · 90% CI -1.21 to 0.53
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.81 · 90% CI -1.64 to 0.02
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.15 · 90% CI -0.72 to 1.02
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.22 · 90% CI -0.70 to 1.15
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.56 · 90% CI -1.44 to 0.32
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.09 · 90% CI -0.83 to 1.01
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.05 · 90% CI -0.39 to 0.49
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.32 · 90% CI -0.75 to 0.10
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.02 · 90% CI -0.46 to 0.42
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.10 · 90% CI -0.65 to 0.45
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.80 · 90% CI -1.33 to -0.27
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.36 · 90% CI -0.91 to 0.19
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.32 · 90% CI -0.36 to 1.00
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.94 · 90% CI -1.59 to -0.29
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.29 · 90% CI -0.97 to 0.39
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.55 · 90% CI -0.20 to 1.30
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.69 · 90% CI -1.41 to 0.04
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.10 · 90% CI -0.85 to 0.66
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.15 · 90% CI -0.96 to 0.66
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.11 · 90% CI -1.89 to -0.33
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.30 · 90% CI -1.13 to 0.52
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.05 · 90% CI -0.86 to 0.95
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.87 · 90% CI -1.73 to -0.01
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.12 · 90% CI -0.78 to 1.03
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.39 · 90% CI -0.60 to 1.39
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.95 · 90% CI -1.90 to 0.00
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.01 · 90% CI -1.00 to 0.99
SecondaryLeast Squares Mean of Absolute Score in Dermatology Life Quality Index (DLQI) Total Score up to Week 16 - MMRM (FAS, OBS)

The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes.

Time frame:
At weeks 4, 8, 12 and 16
Reported as:
Least squares mean · Units on a scale
Least Squares Mean of Absolute Score in Dermatology Life Quality Index (DLQI) Total Score up to Week 16 - MMRM (FAS, OBS)
Units on a scalePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 4-Absolute Score10.2 (8.6 to 11.7)10.6 (9.0 to 12.2)9.6 (8.1 to 11.2)11.1 (9.4 to 12.8)
Week 8-Absolute Score10.8 (9.3 to 12.3)10.2 (8.7 to 11.8)9.6 (8.1 to 11.2)10.8 (9.2 to 12.4)
Week 12-Absolute Score10.7 (9.1 to 12.3)9.9 (8.1 to 11.7)8.7 (7.1 to 10.4)10.5 (8.7 to 12.2)
Week 16-Absolute Score9.5 (7.8 to 11.1)11.2 (9.4 to 13.1)8.2 (6.5 to 10.0)9.5 (7.7 to 11.4)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.4 · 90% CI -1.7 to 2.6
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.5 · 90% CI -2.7 to 1.7
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.9 · 90% CI -1.4 to 3.2
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.5 · 90% CI -2.7 to 1.6
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.1 · 90% CI -3.3 to 1.0
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.0 · 90% CI -2.2 to 2.2
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.8 · 90% CI -3.2 to 1.6
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -2.0 · 90% CI -4.3 to 0.3
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.2 · 90% CI -2.6 to 2.2
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 1.7 · 90% CI -0.7 to 4.2
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.2 · 90% CI -3.6 to 1.2
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.1 · 90% CI -2.4 to 2.6
SecondaryLeast Squares Mean of Change From Baseline in DLQI Total Score up to Week 16 - MMRM (FAS, OBS)

The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined a change from baseline in total score, where negative value means improvement in DLQI.

Time frame:
At weeks 4, 8, 12 and 16
Reported as:
Least squares mean · Units on a scale
Least Squares Mean of Change From Baseline in DLQI Total Score up to Week 16 - MMRM (FAS, OBS)
Units on a scalePlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 4-Change from Baseline-5.5 (-7.1 to -4.0)-5.1 (-6.7 to -3.5)-6.1 (-7.6 to -4.5)-4.6 (-6.3 to -2.9)
Week 8-Change from Baseline-4.9 (-6.4 to -3.4)-5.5 (-7.0 to -3.9)-6.1 (-7.6 to -4.5)-4.9 (-6.5 to -3.3)
Week 12-Change from Baseline-5.0 (-6.6 to -3.4)-5.8 (-7.6 to -4.0)-6.9 (-8.6 to -5.3)-5.2 (-7.0 to -3.5)
Week 16-Change from Baseline-6.2 (-7.9 to -4.5)-4.5 (-6.3 to -2.6)-7.5 (-9.2 to -5.7)-6.2 (-8.0 to -4.3)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.4 · 90% CI -1.7 to 2.6
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -0.5 · 90% CI -2.7 to 1.7
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.9 · 90% CI -1.4 to 3.2
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.5 · 90% CI -2.7 to 1.6
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.1 · 90% CI -3.3 to 1.0
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.0 · 90% CI -2.2 to 2.2
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): -0.8 · 90% CI -3.2 to 1.6
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -2.0 · 90% CI -4.3 to 0.3
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -0.2 · 90% CI -2.6 to 2.2
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 1.7 · 90% CI -0.7 to 4.2
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): -1.2 · 90% CI -3.6 to 1.2
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 0.1 · 90% CI -2.4 to 2.6
SecondaryPercentage of Participants Achieving DLQI Total Score of 0 or 1 up to Week 16 - MR (FAS With Baseline >1, NRI)

The Dermatology Life Quality Index (DLQI) is a general dermatology questionnaire that consists of 10 items that assess patient health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment) over the last week. Scoring for each item is on a qualitative 0 to 3 scale, with options of "Not at all", "A little", "A lot", "Very much". The scores are added up to a total composite score with the range from the minimum score of 0 to the maximum score of 30. The higher the score, the worse the outcomes. The assessments examined the percentage of patients with complete resolution of dermatology specific quality of life impact, as assessed by a total score of ≤ 1 (range: 0 - 30), where higher percentage indicates better improvement in DLQI.

Time frame:
At weeks 4, 8, 12 and 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving DLQI Total Score of 0 or 1 up to Week 16 - MR (FAS With Baseline >1, NRI)
Percentage of ParticipantsPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Week 46.8 (2.5 to 16.6)6.8 (2.5 to 16.6)8.9 (3.9 to 18.0)2.3 (0.2 to 9.4)
Week 82.2 (0.2 to 9.2)6.8 (2.5 to 16.6)8.7 (3.8 to 17.6)4.7 (1.2 to 13.2)
Week 124.4 (1.2 to 12.6)13.6 (6.1 to 24.3)10.9 (5.4 to 21.3)7.0 (2.6 to 17.0)
Week 164.4 (1.2 to 12.6)4.5 (1.2 to 12.9)10.9 (5.4 to 21.3)11.6 (5.8 to 22.9)
Statistical analysis
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.2 · 90% CI -9.1 to 9.5
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 1.2 · 90% CI -7.4 to 9.8
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): -4.0 · 90% CI -11.4 to 3.4
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 4.3 · 90% CI -3.3 to 11.8
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 6.2 · 90% CI -1.8 to 14.2
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 2.5 · 90% CI -4.8 to 9.8
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 7.6 · 90% CI -1.3 to 16.5
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 6.9 · 90% CI -2.0 to 15.7
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 2.9 · 90% CI -5.5 to 11.3
  • Placebo vs PF-06650833 400mg QD · Risk difference (rd): 0.1 · 90% CI -6.3 to 6.4
  • Placebo vs PF-06700841 45mg QD · Risk difference (rd): 6.5 · 90% CI -2.8 to 15.7
  • Placebo vs PF-06826647 400mg QD · Risk difference (rd): 7.6 · 90% CI -1.6 to 16.9
SecondaryPlasma Concentration Versus Time Summary (Pharmacokinetic Concentration Set)

In summary statistics for pharmacokinetic, concentration values below the lower limit of quantification (LLOQ) was set to zero.

Time frame:
At weeks 1, 2, 4, 6, 8, 12 and 16
Reported as:
Mean · Nanograms per milliliter (ng/ml)
Plasma Concentration Versus Time Summary (Pharmacokinetic Concentration Set)
Nanograms per milliliter (ng/ml)PF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
WEEK 1 0H31.79 ± 26.56749.22 ± 64.871281.7 ± 364.14
WEEK 2 0H30.48 ± 35.79651.48 ± 76.426263.8 ± 388.42
WEEK 4 0H25.33 ± 25.79563.60 ± 77.180215.6 ± 259.41
WEEK 6 0H27.25 ± 29.90547.38 ± 61.091113.5 ± 140.62
WEEK 8 0H34.72 ± 35.70060.30 ± 92.758277.2 ± 316.40
WEEK 8 30MIN28.58 ± 24.510254.7 ± 157.30667.4 ± 560.37
WEEK 8 1H45.70 ± 33.027373.4 ± 174.51817.2 ± 573.70
WEEK 8 2H94.89 ± 48.222296.0 ± 173.76869.6 ± 549.58
WEEK 8 4H112.4 ± 103.09231.7 ± 168.11784.8 ± 548.33
WEEK 12 0H34.34 ± 32.04652.95 ± 82.248233.1 ± 322.19
WEEK 16 0H39.41 ± 36.77343.89 ± 67.413244.4 ± 296.93

Adverse events

Collected over Up to 20 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/48 (0%)0/48 (0%)6/48 (12.5%)
PF-06650833 400mg QD0/47 (0%)2/47 (4.3%)10/47 (21.3%)
PF-06700841 45mg QD0/52 (0%)0/52 (0%)14/52 (26.9%)
PF-06826647 400mg QD0/47 (0%)2/47 (4.3%)18/47 (38.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
COVID-19Infections and infestations0/480/470/521/47
CellulitisInfections and infestations0/481/470/520/47
Suicidal ideationPsychiatric disorders0/481/470/520/47
HidradenitisSkin and subcutaneous tissue disorders0/480/470/521/47
Most frequent other events
Most frequent other events
EventPlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QD
Blood creatine phosphokinase increasedInvestigations0/480/474/526/47
HidradenitisSkin and subcutaneous tissue disorders2/481/471/526/47
HeadacheNervous system disorders3/485/474/523/47
AcneSkin and subcutaneous tissue disorders1/484/475/524/47
NauseaGastrointestinal disorders0/481/471/523/47
Urinary tract infectionInfections and infestations1/483/472/520/47

Baseline characteristics

All enrolled participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)PlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QDTotal
Mean37.0 ± 8.9539.9 ± 12.6638.0 ± 11.7636.6 ± 10.7237.9 ± 11.10
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QDTotal
Female42344035151
Male613121243
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QDTotal
Hispanic or Latino7137835
Not Hispanic or Latino41344338156
Unknown or Not Reported00213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPF-06650833 400mg QDPF-06700841 45mg QDPF-06826647 400mg QDTotal
White32262628112
Black1318241469
Asian20136
American Indian or Alaska Native10102
Multiracial (Asian, White)00011
Not reported03014
08

Study locations

77 sites
  • The University Of Alabama At Birmingham
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham Hospital Outreach Lab
    Birmingham, Alabama 35249, United States
  • The University of Alabama at Birmingham Investigation Drug Services Pharmacy
    Birmingham, Alabama 35249, United States
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Pacific Clinical Trials
    Long Beach, California 90806, United States
  • Keck School of Medicine of University of Southern California
    Los Angeles, California 90033, United States
  • UCSF Dermatology Clinic
    San Francisco, California 94115, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • UCSF Psoriasis and Skin Treatment Center
    San Francisco, California 94118, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • New England Research Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • Dermatology Physicians of Connecticut
    Shelton, Connecticut 06484, United States
  • Total Dermatology Care Center
    Jacksonville, Florida 32204, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Olympian Clinical Research Largo Office
    Largo, Florida 33770, United States
  • University of Miami Hospital
    Miami, Florida 33125, United States
  • Tory Sullivan MD PA
    North Miami Beach, Florida 33162, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • MidState Skin Institute
    Ocala, Florida 34471, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Leavitt Medical Associates of Florida d/b/a Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Riverchase Dermatology and Cosmetic Surgery
    Pembroke Pines, Florida 33028, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Alliance Clinical Research of Tampa
    Tampa, Florida 33615, United States
  • MedaPhase Inc.
    Newnan, Georgia 30263, United States
  • Advanced Medical Research PC
    Sandy Springs, Georgia 30328, United States
  • Georgia Skin Cancer and Aesthetic Dermatology
    Watkinsville, Georgia 30677, United States
  • NorthShore University HealthSystem Dermatology Clinic
    Skokie, Illinois 60077, United States
  • Ds Research
    Clarksville, Indiana 47129, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Boston University General Clinical Research Unit
    Boston, Massachusetts 02118, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Wayne State University / Integrative Biosciences Center
    Detroit, Michigan 48202, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • Clinical Research Unit
    Minneapolis, Minnesota 55455, United States
  • Lillihei Clinical Research Unit
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Department of Dermatology
    Minneapolis, Minnesota 55455, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Saint Louis University - Department of Dermatology
    Saint Louis, Missouri 63110, United States
  • Skin Specialists PC
    Omaha, Nebraska 68144, United States
  • J Woodson Clinical Studies Group
    Henderson, Nevada 89052, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Vital Prospects Clinical Research Institute
    Tulsa, Oklahoma 74136, United States
  • Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Penn State Health Radiology - University Physician Center
    Hershey, Pennsylvania 17033, United States
  • Paddington Testing Company, Inc
    Philadelphia, Pennsylvania 19103, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Dermatology and Skin Cancer Consultants
    Humboldt, Tennessee 38343, United States
  • Clinical Research Solutions
    Jackson, Tennessee 38305, United States
  • Dermatology and Skin Cancer Consultants
    Jackson, Tennessee 38305, United States
  • Arlington Research Center
    Arlington, Texas 76011, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • University of Utah MidValley Dermatology
    Murray, Utah 84107, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298, United States
  • Bellevue Dermatology Clinical Research Center
    Bellevue, Washington 98004, United States
  • Bellevue Dermatology Clinic
    Bellevue, Washington 98004, United States
  • Dermatology Associates of Seattle
    Seattle, Washington 98101, United States
  • Woden Dermatology
    Phillip, Australian Capital Territory 2606, Australia
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 2217, Australia
  • Holdsworth House Medical Practice
    Sydney, New South Wales 2010, Australia
  • Veracity Clinical Research
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute Inc.
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • SimcoDerm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • Manna Research (London)
    London, Ontario N6A 2C2, Canada
  • DermEffects
    London, Ontario N6H 5L5, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Centre de Recherche Saint-Louis
    Quebec, G1W4R4, Canada
  • Alpha Recherche Clinique
    Quebec, G2J 0C4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jan 2022, 25 months.

Results were first posted in Jun 2023, 1 year 5 months after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 25 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2019
First posted
Sep 17, 2019
StartActual
Dec 2, 2019
Primary completionActual
Jan 10, 2022
CompletionActual
Jan 10, 2022
Results first posted
Jun 15, 2023
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04092452
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Dec 2, 2019
Primary completion
Jan 10, 2022
Completion
Jan 10, 2022
Results posted
Jun 15, 2023
Last update
Jun 15, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zimlovisertib · PF-06700841 · Ropsacitinib

Start the discussion